248 related articles for article (PubMed ID: 24112092)
1. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
[TBL] [Abstract][Full Text] [Related]
2. Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line.
Yang X; Lin J; Gong Y; Ma H; Shuai X; Zhou R; Guo Y; Shan Q; He G
Hematol Oncol; 2012 Sep; 30(3):123-30. PubMed ID: 21898527
[TBL] [Abstract][Full Text] [Related]
3. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
4. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor.
Hirase C; Maeda Y; Takai S; Kanamaru A
Leuk Res; 2009 Mar; 33(3):450-9. PubMed ID: 18783828
[TBL] [Abstract][Full Text] [Related]
6. The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line.
Xing H; Yang X; Liu T; Lin J; Chen X; Gong Y
Leuk Res; 2012 Apr; 36(4):509-13. PubMed ID: 22285507
[TBL] [Abstract][Full Text] [Related]
7. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia.
Stoklosa T; Glodkowska-Mrowka E; Hoser G; Kielak M; Seferynska I; Wlodarski P
Exp Hematol; 2013 May; 41(5):462-9. PubMed ID: 23395818
[TBL] [Abstract][Full Text] [Related]
8. [Effect of VE-cadherin on sensitivity to Imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
Zhang HX; Yan ZL; Song XG; Lü C; Cao J; Li ZY; Zeng LY; Chen C; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):522-6. PubMed ID: 23827112
[TBL] [Abstract][Full Text] [Related]
9. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
10. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
Guo Y; Li Y; Xiang B; Huang XO; Ma HB; Wang FF; Gong YP
Biochem J; 2017 Dec; 474(24):4153-4170. PubMed ID: 29046392
[TBL] [Abstract][Full Text] [Related]
11. Roots of imatinib resistance: a question of self-renewal?
Burchert A
Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
[TBL] [Abstract][Full Text] [Related]
12. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
[TBL] [Abstract][Full Text] [Related]
13. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
14. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Li J; Xue L; Hao H; Han Y; Yang J; Luo J
Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
[TBL] [Abstract][Full Text] [Related]
16. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
Hawkins LM; Jayanthan AA; Narendran A
Pediatr Res; 2005 Mar; 57(3):430-7. PubMed ID: 15659698
[TBL] [Abstract][Full Text] [Related]
17. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
Mayerhofer M; Aichberger KJ; Florian S; Krauth MT; Hauswirth AW; Derdak S; Sperr WR; Esterbauer H; Wagner O; Marosi C; Pickl WF; Deininger M; Weisberg E; Druker BJ; Griffin JD; Sillaber C; Valent P
FASEB J; 2005 Jun; 19(8):960-2. PubMed ID: 15784722
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
19. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
[TBL] [Abstract][Full Text] [Related]
20. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
